XTL Biopharmaceuticals Announces Appointment of Samuel H. Rudman to Board of Directors
15 August 2008 - 6:05AM
PR Newswire (US)
VALLEY COTTAGE, N.Y., Aug. 14 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced
that Samuel H. Rudman, Esq., has been appointed to XTL's Board of
Directors, effective as of August 13, 2008. Mr. Rudman, 40, is a
named partner at a U.S. law firm specializing in complex
litigation, emphasizing securities, consumer, insurance,
healthcare, human rights, employment discrimination and antitrust
class actions. Mr. Rudman's practice is focused primarily on the
area of securities and shareholder litigation, and complex issues
of disclosure and corporate governance. Mr. Rudman graduated with a
BA in political science from Binghamton University and with a JD
from Brooklyn Law School. Ron Bentsur, Chief Executive Officer of
XTL, commented "We are excited to have Sam join our Board of
Directors. Sam is well-versed in matters related to corporate
governance. We believe that his skills provide a valuable addition
to XTL's Board, as we prepare for the next stage of the company's
growth following what we hope will be a successful completion of
our Phase 2b study of Bicifadine in Q4 2008." ABOUT XTL
BIOPHARMACEUTICALS LTD. XTL Biopharmaceuticals Ltd. ("XTL") is
engaged in the development of therapeutics for the treatment of
diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a
serotonin and norepinephrine reuptake inhibitor, for the treatment
of diabetic neuropathic pain, which is currently in a Phase 2b
study. XTL has out-licensed its novel pre-clinical HCV small
molecule inhibitor program. XTL also has an active in-licensing and
acquisition program designed to identify and acquire additional
drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv
Stock Exchanges (NASDAQ:XTLB)(TASE:XTL). Cautionary Statement Some
of the statements included in this press release, particularly
those anticipating future clinical and business prospects for our
clinical compound for neuropathic pain, Bicifadine, growth and
operating strategies and similar matters, may be forward-looking
statements that involve a number of risks and uncertainties. For
those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Among the factors that could cause
our actual results to differ materially is our ability to complete
in a timely and cost effective manner clinical trials on
Bicifadine, which could directly impact our ability to continue to
fund our operations; our ability to meet anticipated development
timelines for all of our drug candidates due to recruitment,
clinical trial results, manufacturing capabilities or other
factors; our ability to obtain regulatory approvals for commercial
sale of our products; the success of our drug development and
marketing arrangements with third parties; and other risk factors
identified from time to time in our reports filed with the
Securities and Exchange Commission, including our annual report on
Form 20-F filed with the Securities and Exchange Commission on
March 27, 2008. Any forward-looking statements set forth in this
press release speak only as of the date of this press release. We
do not intend to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof.
This press release and prior releases are available at
http://www.xtlbio.com/. The information in our website is not
incorporated by reference into this press release and is included
as an inactive textual reference only. DATASOURCE: XTL
Biopharmaceuticals Ltd. CONTACT: Ron Bentsur, Chief Executive
Officer, XTL Biopharmaceuticals Ltd., +1-845-267-0707 ext. 225 Web
site: http://www.xtlbio.com/
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024